Efficacy and tolerability of captopril oinment 0,1% og 0,3% in atopic dermatitis. A randomised, double-blind, placebocontrolled, doseescalating, intra-individual clinical study.

ACE Aps0 个研究点开始时间: 2008年7月24日最近更新: 2012年11月5日

适应症

试验速览

暂无简介。

•Patients with chronic active atopic eczema in spots or spread symmetrical on the arms.
•Age 18-80 (both included)
•White (Caucasian)
•Normal weight
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Acute eczema, requiring active dermatological treatment
•Other skin disease (e.g. contact allergy, urticaria, psoriasis)
•Dermatological lighttreatment or use of solarium 4 weeks prior to the trial.
•Known hypersensitivity to any constituents or active ingredients in teh amounts present in the trial medication
•Known coronary heart disease
•Alcohol abuse or other type of abuse or dependency
•Participation in a clinical trial within 30 days prior to inclusion in the trial.
•Lack of use of safe anticonception unless the trial subject is sterile or in the postmenopause. Safe anticonception is: p-pills, Intra Uterine Device, depot injection of gestagen, subdermal implantation, hormonal vaginalring and transdermal depotplaster

发起方

ACE Aps